# Shirish M. Gadgeel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/shirish-m-gadgeel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 43,144 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 79 |
| i10-index | 293 |
| Last Known Institution | Henry Ford Health System |
| OpenAlex ID | https://openalex.org/A5025836672 |
| ORCID iD | https://orcid.org/0000-0001-5240-3811 |
| Works | 859 |

## Researcher papers

Showing 12 of 17.

- [Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/)
- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/alectinib-versus-crizotinib-in-untreated-i-alk-i-positive-non-small-cell-lung/)
- [Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/updated-analysis-from-keynote-189-pembrolizumab-or-placebo-plus-pemetrexed-and/)
- [Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer](https://scholariq.org/papers/molecular-mechanisms-of-resistance-to-first-and-second-generation-alk-inhibitors/)
- [Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation](https://scholariq.org/papers/adagrasib-in-non-small-cell-lung-cancer-harboring-a-i-kras-sup-g12c-sup-i/)
- [Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study](https://scholariq.org/papers/lorlatinib-in-patients-with-alk-positive-non-small-cell-lung-cancer-results-from/)
- [Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study](https://scholariq.org/papers/updated-overall-survival-and-final-progression-free-survival-data-for-patients/)
- [Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study](https://scholariq.org/papers/safety-and-activity-of-alectinib-against-systemic-disease-and-brain-metastases/)
- [Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study](https://scholariq.org/papers/pembrolizumab-plus-pemetrexed-and-platinum-in-nonsquamous-non-small-cell-lung/)
- [Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/rociletinib-in-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial](https://scholariq.org/papers/alectinib-in-alk-positive-crizotinib-resistant-non-small-cell-lung-cancer-a/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Henry Ford Health System](https://scholariq.org/institutions/henry-ford-health-system/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.